A leading Harvard researcher has issued a clear warning. Youth substance use prevention is not receiving the sustained investment it needs. Young people continue to fall through the cracks at every stage of care.

Dr John F Kelly is the founder of the Recovery Research Institute and the National Center on Youth Prevention, Treatment, and Recovery at Massachusetts General Hospital. He spoke recently on The State of Mental Wellbeing, a podcast from the National Council. Guest host Philip Rutherford, VP of Growth and Substance Use Strategy at the National Council, led the conversation. Together they examined the current evidence, the risks that concern researchers most today, and what needs to change.

A Research Community That Lost Focus

In the 1990s and early 2000s, a strong cohort of scientists was actively developing validated tools and age-specific treatments for adolescents. Over time, that community dispersed into other areas. Youth substance use prevention gradually lost momentum as a dedicated field of study.

“There was a bit of a gap that opened up,” Dr Kelly said. “We need to regenerate the field.”

That insight led him to found the National Center on Youth Prevention, Treatment, and Recovery. The centre has since run three national conferences in Baltimore, drawing growing numbers of clinicians, researchers, and policymakers. Dr Kelly also described the work as an effort to attract a new generation of researchers into this space, which he considers genuinely underserved.

Rising Risks: Cannabis, Polysubstance Use, and Screen Time

Several risks dominated the discussion. High-potency cannabis came near the top.

THC concentrations in cannabis have quadrupled since the 1970s and 80s. The product widely available today is fundamentally different from the substance that featured in earlier research. Dr Kelly argued that this shift carries significant consequences for young people.

“Toxicity is in the dose,” he said. “Higher exposure at younger ages creates enormous risks, not just for addiction but for epigenetic effects that may activate genes not normally turned on, particularly around psychosis and anxiety disorders.”

Rutherford noted that psychiatric admissions linked to adolescent cannabis use are rising sharply, a pattern clinicians across several countries are now tracking closely.

Polysubstance use is also a growing concern. Vaping, alcohol, synthesised compounds, and high-potency cannabis can all be present at once. However, this combination makes clinical assessment far harder than when only one substance is involved. Any serious approach to youth substance use prevention must therefore account for this shifting landscape. Dr Kelly additionally raised the question of heavy screen time and social media exposure during childhood. While the science here is still developing, he described it as a serious open question given what is known about the developing brain.

Diagnostic Criteria Not Built for Adolescents

Accurate assessment underpins both youth substance use prevention and effective treatment. However, Dr Kelly raised serious questions about the diagnostic criteria used to identify substance use disorder in young people. These criteria were largely developed from research into middle-aged adults with severe alcohol dependence.

“You cannot ask a 16-year-old how it feels when they miss their mortgage payment because of their substance use,” he said. “They simply do not know what you are talking about.”

This mismatch distorts clinical pictures and can produce inaccurate diagnoses. Furthermore, adult treatment models have too often been scaled down for adolescents without fundamentally reconsidering whether the underlying concepts apply at all. Adolescent substance use recovery requires genuinely different frameworks, not a condensed version of adult care.

The Gap Between Evidence and Practice in Medications

Medications for young people with severe opioid use disorder are available. Buprenorphine and naloxone are approved for those aged 16 and over who meet clinical criteria. Yet a persistent gap exists between the number who qualify and those who actually receive treatment, revealing one of the clearest failures in youth substance use prevention and care.

Dr Kelly pointed to research suggesting only 15 to 20 per cent of adults who meet criteria for opioid medications actually receive them. The figure is even lower for alcohol use disorder, despite alcohol causing far higher absolute mortality. He suggested the same pattern applies among younger populations.

Reasons include patient reluctance and clinician resistance toward agonist-based treatments such as methadone and buprenorphine. Some practitioners hold ideological objections even when the evidence is clear. Training can shift these attitudes over time, but progress remains slow.

Challenging the Idea That It Is Inevitable

Asked to name one misconception he would most want to eliminate, Dr Kelly identified the belief that substance use among young people is simply a rite of passage, something that will happen regardless of what adults do.

“It is not inevitable,” he said. “If you look at data from 1900 to 1950, adolescents and young adults had the lowest rates of substance use on record.”

From 1960 onwards, rates rose sharply. The increase includes a tripling of disorder rates among women. That trajectory reflects cultural and societal conditions, not biology. He stressed that treating substance use as inevitable weakens political will for prevention investment. It also discourages family and community action, which the evidence suggests can make a real difference.

“As parents, you can have a powerful influence on the likelihood that your child will use substances,” he said.

Recovery Support: The Most Underbuilt Part of the System

Dr Kelly acknowledged real progress in prevention research and acute treatment over recent decades. However, he was clear that recovery support services for young people remain the most underdeveloped area.

Adolescent substance use recovery must account for very different life circumstances than adult recovery. School attendance, family dependency, and social development all shape what is useful. Community activities and recreational programmes that offer alternatives to substance-using environments matter greatly at this stage. Yet relatively few such programmes have been rigorously evaluated for this age group.

“We need to create services and activities that will attract and engage young people sooner into recovery,” he said.

Why Screening Needs to Start Sooner

Closing the conversation, Dr Kelly drew a comparison with cancer screening. Public health systems schedule screenings at the ages when risk is known to peak. Similarly, the same logic should apply to substance use disorder. The critical window for onset falls roughly between ages 15 and 25.

“That is where we need to be much more assertive in terms of screening and early intervention,” he said, “to offset what could be a deleterious and deadly course.”

Rutherford agreed, noting that early onset of substance use disorder is among the strongest known predictors of longer-term harm. For youth substance use prevention to fulfil its potential, earlier detection must therefore sit at the centre of any serious national strategy.

Source: dbrecoveryresources